286 related articles for article (PubMed ID: 9426522)
1. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
2. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
3. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
4. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas.
Gaffey MJ; Mills SE; Swanson PE; Zarbo RJ; Shah AR; Wick MR
Am J Surg Pathol; 1992 Jun; 16(6):593-9. PubMed ID: 1599037
[TBL] [Abstract][Full Text] [Related]
6. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
[TBL] [Abstract][Full Text] [Related]
8. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
9. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma.
Sheibani K; Shin SS; Kezirian J; Weiss LM
Am J Surg Pathol; 1991 Aug; 15(8):779-84. PubMed ID: 2069213
[TBL] [Abstract][Full Text] [Related]
10. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
[TBL] [Abstract][Full Text] [Related]
12. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
13. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
14. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.
Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF
Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250
[TBL] [Abstract][Full Text] [Related]
16. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
17. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin.
Attanoos RL; Goddard H; Thomas ND; Jasani B; Gibbs AR
Histopathology; 1995 Oct; 27(4):361-6. PubMed ID: 8847067
[TBL] [Abstract][Full Text] [Related]
18. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
[TBL] [Abstract][Full Text] [Related]
19. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
Naso JR; Churg A
Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
[TBL] [Abstract][Full Text] [Related]
20. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
